Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy
Conditions
Interventions
YL202
Eribulin
+4 more
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Start Date
March 10, 2026
Primary Completion Date
December 31, 2027
Completion Date
June 30, 2028
Last Updated
March 10, 2026
NCT07354022
NCT02926690
NCT06680921
NCT05744687
NCT02514681
NCT03027245
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions